Antibody

1,010개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,010 programs
AntibodyCurated CoreFDASanofiApproved

alirocumab (Praluent, REGN727, SAR236553)

Hyperlipidemia, ASCVD, HeFH · PCSK9

#PCSK9#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 103Status Approved
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

guselkumab (Tremfya, CNTO 1959)

Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 87Status Approved
AntibodyCurated CoreFDANovartisApproved

inclisiran (Leqvio, KJX839, ALN-PCS)

Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) · PCSK9 (siRNA)

#PCSK9siRNA#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 72Status Approved
AntibodyCurated CoreFDAUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyCurated CoreFDARocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
AntibodyCurated CoreFDAargenxApproved

efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab)

Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy · FcRn (neonatal Fc receptor)

#FcRnneonatalFcreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
AntibodyCurated CoreFDAAstraZenecaApproved

tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko)

Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps · TSLP (thymic stromal lymphopoietin)

#TSLPthymicstromallymphopoietin#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
AntibodyCurated CoreFDAEisaiApproved

lecanemab (Leqembi, BAN2401, lecanemab-irmb)

Early symptomatic Alzheimer's disease (MCI or mild dementia) with confirmed amyloid pathology · Amyloid-beta protofibrils

#Amyloid-betaprotofibrils#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 37Status Approved
AntibodyCurated CoreFDAJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

nipocalimab (Imaavy, M281, nipocalimab-aahu)

Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia · FcRn

#FcRn#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 27Status Approved
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
AntibodyCurated CoreFDARegeneronApproved

linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)

Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved
AntibodyCurated CoreFDAEli LillyApproved

donanemab (Kisunla, LY3002813, donanemab-azbt)

Early symptomatic Alzheimer's disease with confirmed amyloid pathology · N3pG amyloid-beta plaque

#N3pGamyloid-betaplaque#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 21Status Approved
AntibodyCurated CoreRochePhase 2

Avastin (Avastin)

Neovascular Age-Related Macular Degeneration · Extranodal NK/T-cell Lymphoma, Nasal Typ

#ExtranodalNKT-cellLymphomaNasalT#Antibody#Phase2#BioJungboMoa-pick#Popular+3
Trials 1444Status Active
AntibodyCurated CoreRocheApproved

rituximab (Rituxan)

Rheumatoid Arthritis · Pompe Disease

#PompeDisease#Antibody#Approved#BioJungboMoa-pick#Popular+4
Trials 1337Status Active
AntibodyCurated CoreEli LillyPhase 3

Erbitux (Erbitux)

Head and Neck Cancer Squamous Cell · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 942Status Recruiting
AntibodyCurated CoreBristol Myers SquibbPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 470Status Active

2 / 51 pages

← PreviousNext →